Author | Jeremy S. Abramson, MD | OncLive

Author | Jeremy S. Abramson, MD

Articles

Dr. Abramson on the TRANSCEND NHL 001 Trial in Large B-Cell Lymphoma

February 15, 2020

Video

Jeremy S. Abramson, MD, discusses the results of the multicenter phase I TRANSCEND NHL 001 study evaluating the safety and efficacy of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

Dr. Abramson on Safety and Efficacy of Liso-Cel in Relapsed/Refractory Large B-Cell Lymphoma

December 09, 2019

Video

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the pivotal safety and efficacy results from phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory large B-cell lymphoma.

Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL

July 10, 2018

Video

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses lisocabtagene maraleucel (JCAR017; liso-cel) as a treatment for patients with non-Hodgkin lymphoma.

Dr. Abramson on TRANSCEND on JCAR017 Therapy in NHL

June 19, 2017

Video

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

x